{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T22:47:10Z","timestamp":1773787630652,"version":"3.50.1"},"reference-count":15,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2013,9,7]],"date-time":"2013-09-07T00:00:00Z","timestamp":1378512000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"name":"Laboratoires Carilene"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Acad Dermatol Venereol"],"published-print":{"date-parts":[[2014,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Topical or systemic antiviral drugs reduce the duration of genital herpes recurrences but may not always alleviate functional symptoms.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objectives<\/jats:title><jats:p>To assess the efficacy and safety of oxygenated glycerol triesters\u2010based <jats:styled-content style=\"fixed-case\">CS<\/jats:styled-content>21 barrier genital gel<jats:sup>\u00ae<\/jats:sup> vs. topical aciclovir and placebo (vehicle) in resolving functional symptoms and in healing of genital herpes recurrences.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A prospective randomized controlled, investigator\u2010blinded trial of <jats:styled-content style=\"fixed-case\">CS<\/jats:styled-content>21 barrier genital gel<jats:sup>\u00ae<\/jats:sup> vs. topical aciclovir (reference treatment) and placebo (vehicle) was designed. The primary endpoint was the cumulative score of four herpes\u2010related functional symptoms (pain, burning, itching and tingling sensations). Secondary endpoints included objective skin changes (erythema, papules, vesicles, oedema, erosion\/ulceration, crusts), time to heal, local tolerance and overall acceptability of the treatment as reported by a self\u2010administered questionnaire.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Overall, 61 patients were included. <jats:styled-content style=\"fixed-case\">CS<\/jats:styled-content> 21 barrier genital gel<jats:sup>\u00ae<\/jats:sup> was significantly more efficient than topical aciclovir and vehicle for subjective symptoms and pain relief in genital herpes recurrences; additionally, time to heal was significantly shorter with <jats:styled-content style=\"fixed-case\">CS<\/jats:styled-content> 21 than with vehicle, whereas no significantly difference was observed between patients receiving topical aciclovir and vehicle. The treatments under investigation were well tolerated and the adverse events were comparable in the three treatment groups.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Overall, these results support the interest of using of <jats:styled-content style=\"fixed-case\">CS<\/jats:styled-content> 21 barrier genital gel<jats:sup>\u00ae<\/jats:sup> in symptomatic genital herpes recurrences. Accordingly, this product offers a valuable alternative in topical management of recurrent genital herpes.<\/jats:p><\/jats:sec>","DOI":"10.1111\/jdv.12228","type":"journal-article","created":{"date-parts":[[2013,9,7]],"date-time":"2013-09-07T06:03:25Z","timestamp":1378533805000},"page":"1158-1164","source":"Crossref","is-referenced-by-count":5,"title":["Evaluation of the activity and safety of <scp>CS<\/scp> 21 barrier genital gel<sup>\u00ae<\/sup> compared to topical aciclovir and placebo in symptoms of genital herpes recurrences: a randomized clinical trial"],"prefix":"10.1111","volume":"28","author":[{"given":"A.","family":"Khemis","sequence":"first","affiliation":[{"name":"Service de Dermatologie H\u00f4pital L'Archet 2 Nice Cedex 3 France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Duteil","sequence":"additional","affiliation":[{"name":"CPCAD H\u00f4pital L'Archet 2 Nice Cedex 3 France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Y.","family":"Tillet","sequence":"additional","affiliation":[{"name":"White\u2010Tillet Consultants &amp; Experts 35 Chelles France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"O.","family":"Dereure","sequence":"additional","affiliation":[{"name":"Service de Dermatologie H\u00f4pital Saint\u2010Eloi Montpellier Cedex 5 France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J\u2010P.","family":"Ortonne","sequence":"additional","affiliation":[{"name":"Service de Dermatologie H\u00f4pital L'Archet 2 Nice Cedex 3 France"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2013,9,7]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1093\/ije\/26.4.698"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)61908-4"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.168.11.1137"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1586\/14787210.1.2.283"},{"issue":"4","key":"e_1_2_6_6_1","first-page":"635","article-title":"Local treatments using antiviral and non\u2010antiviral drugs for herpes facialis and genitalis (excluding pregnant females and neonates at risk)","volume":"129","author":"Chosidow O","year":"2002","journal-title":"Ann Dermatol Venereol"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/12.suppl_B.67"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/0166-3542(83)90037-2"},{"key":"e_1_2_6_9_1","first-page":"58","article-title":"Topical acyclovir in the treatment of recurrent herpes simplex virus infections","volume":"47","author":"Kinghorn GR","year":"1985","journal-title":"Scand J Infect Dis Suppl"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198206033062201"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(82)90117-6"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/147.2.336"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/150.1.1"},{"key":"e_1_2_6_14_1","first-page":"437","article-title":"Efficacy of a new oral lubricant solution in the management of psychotropic drug\u2010induced xerostomia: a randomised clinical trial","volume":"27","author":"Mouly SJ","year":"2007","journal-title":"J Clin Pharmacol"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.2011.04269.x"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.25.1.10"}],"container-title":["Journal of the European Academy of Dermatology and Venereology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjdv.12228","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjdv.12228","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jdv.12228","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,24]],"date-time":"2023-09-24T08:49:27Z","timestamp":1695545367000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jdv.12228"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,9,7]]},"references-count":15,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2014,9]]}},"alternative-id":["10.1111\/jdv.12228"],"URL":"https:\/\/doi.org\/10.1111\/jdv.12228","archive":["Portico"],"relation":{},"ISSN":["0926-9959","1468-3083"],"issn-type":[{"value":"0926-9959","type":"print"},{"value":"1468-3083","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,9,7]]}}}